Drugs / HEC89736
last change Sep 2022 re-read 3 minutes ago

HEC89736

Developed for
B-cell neoplasm
Investigated by
Sunshine Lake Pharma Co., Ltd.

Trials 1

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04865458 Apr 2021 → Sep 2022 B-cell neoplasm Sunshine Lake Pharma Co., Ltd. Terminated No outcome recorded Stop: Business

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HEC89736 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04865458 ↗